Compare Crispr Therapeutics AG (CRSP) vs Newegg Commerce Inc (NEGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Newegg Commerce Inc — how do they compare? Crispr Therapeutics AG trades at $53.98 (market cap $5.23B), while Newegg Commerce Inc trades at $19.76 (market cap $398.29M). The key difference: Crispr Therapeutics AG is far larger — about 13.1× Newegg Commerce Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Newegg Commerce Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | NEGG | |
|---|---|---|
Market Cap | $5.23B | $398.29M |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $128.09 |
52-Week Low | $44.34 | $12.87 |
Enterprise Value | $3.65B | $397.09M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Newegg Commerce (NEGG) trades at $19.80, up 7.73% with bullish technical signals and strong recent earnings beats. The stock shows improving fundamentals with revenue stabilizing around $1.4B and net income turning positive in 2026 forecasts. Recent business developments include AI shopping enhancements and exclusive product launches driving growth potential.
Outlook remains cautiously optimistic with improving profitability but carries execution risks. The high P/E ratio of 73.16 suggests premium valuation requiring sustained growth. Key opportunities include technology sector recovery and AI initiatives, while risks involve competitive pressures and cash flow volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Newegg Commerce Inc
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.
Read more on NEGG →
